



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** March 4, 2010

**To:** Principal Investigators  
Primary Clinical Research Associates

**From:** Sara Braun  
Research Protocol Specialist III

**Re:** N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

This memo is being sent to confirm that the Phase II portion of protocol N057K is now open to enrollment at all NCCTG sites.

The Phase II portion was activated to NCCTG with the activation of Addendum 6.